JAMES C BLAIR
CIK 1024000 · last filed 2021-06-11
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$515.04M
Companies
24
Total Filings
127
Lifetime Open-Market Net
$73.71M
Filer Profile
Reported Address
5880 PACIFIC CENTER BLVDSAN DIEGO, CA 92121-4204
State of Incorporation
CA
Related Filers
BRIAN H DOVEY — 202 joint filings, latest 2019-08-08
JESSE I TREU — 201 joint filings, latest 2019-08-08
NICOLE VITULLO — 198 joint filings, latest 2019-08-08
KATHLEEN K SCHOEMAKER — 151 joint filings, latest 2015-08-20
Brian K Halak — 123 joint filings, latest 2019-08-08
PARTERS VII L P DOMAIN — 42 joint filings, latest 2019-08-08
Domain Partners VI, L.P. — 40 joint filings, latest 2017-12-13
DP VI Associates, L.P. — 35 joint filings, latest 2017-12-13
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses.
View filings on SEC EDGAR.
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Clovis Oncology, Inc. (CLVS) Delisted | Director | 53,439 | $0.08 | $4.3K | -$62.21M | 22 | 2021-06-11 |
| LIFE | Director | 129,130 | $40.25 | $5.20M | $0 | 7 | 2019-05-10 |
| Dicerna Pharmaceuticals Inc (DRNA) Delisted | 10%+ Owner | 3,482,033 | $38.22 | $133.08M | $0 | 3 | 2017-12-20 |
| CoLucid Pharmaceuticals, Inc. (CLCD) Delisted | 10%+ Owner | 3,168 | — | — | -$10.4K | 2 | 2016-08-03 |
| Evoke Pharma Inc (OMED) Delisted | 10%+ Owner | 35,296 | — | — | -$1.71M | 5 | 2016-04-21 |
| SNDX | 10%+ Owner | 1,743,854 | $18.18 | $31.70M | $0 | 1 | 2016-03-08 |
| GKOS | 10%+ Owner | 2,077,660 | $167.25 | $347.49M | $0 | 1 | 2015-07-01 |
| Esperion Therapeutics, Inc. (ESPR) Delisted | 10%+ Owner | 2,597,397 | $3.18 | $8.26M | $74.00M | 2 | 2014-10-21 |
| Achaogen, Inc. (AKAO) Delisted | 10%+ Owner | 1,987,049 | — | — | $0 | 1 | 2014-03-17 |
| TNDM | 10%+ Owner | 318,906 | $17.11 | $5.46M | $0 | 1 | 2013-11-19 |
| VCYT | 10%+ Owner | 3,063,294 | $40.87 | $125.20M | $0 | 1 | 2013-11-04 |
| Tobira Therapeutics, Inc. (RGDO) Delisted | 10%+ Owner | 513 | — | — | $3.00M | 1 | 2013-08-28 |
| Ocera Therapeutics, Inc. (TZYM) Delisted | 10%+ Owner | 47,963 | — | — | $8.00M | 1 | 2013-07-16 |
| ALIMERA SCIENCES INC (ALIM) Delisted | 10%+ Owner | 262,599 | $5.54 | $1.45M | -$1.71M | 5 | 2013-06-20 |
| ZOGENIX, INC. (ZGNX) Delisted | Director | 1,240,417 | $26.68 | $33.09M | $16.40M | 6 | 2013-06-19 |
| CADENCE PHARMACEUTICALS INC (CADX) Delisted | Director | 2,417,824 | — | — | $8.10M | 24 | 2013-06-13 |
| ACHILLION PHARMACEUTICALS INC (ACHN) Delisted | 10%+ Owner | 5,772,968 | — | — | $0 | 3 | 2013-01-18 |
| Durata Therapeutics, Inc. (DRTX) Delisted | 10%+ Owner | 2,227,596 | — | — | $7.06M | 1 | 2012-07-24 |
| Orexigen Therapeutics, Inc. (OREX) Delisted | 10%+ Owner | 7,001 | — | — | $24.29M | 14 | 2011-12-22 |
| Paratek Pharmaceuticals, Inc. (NOVC) Delisted | Director | 67,875 | — | — | -$514.6K | 4 | 2009-01-30 |
| Volcano Corp (VOLC) Delisted | Director | 1,939,456 | — | — | -$985.0K | 10 | 2008-07-18 |
| PHARMION CORP (PHRM) Delisted | Director | — | — | — | $0 | 1 | 2007-06-08 |
| NUVASIVE INC (NUVA) Delisted | Director | 3,457 | $39.75 | $137.4K | $0 | 3 | 2007-05-29 |
| SENORX INC (SENO) Delisted | 10%+ Owner | 24,665 | — | — | $0 | 1 | 2007-04-03 |
Recent Filings · Page 10 of 13
127 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2009-11-25 | Orexigen Therapeutics, Inc. (OREX) Delisted | Buy (P) | +50,000 | $337.5K | EDGAR |
| 2009-11-24 | Orexigen Therapeutics, Inc. (OREX) Delisted | Buy (P) | +400,000 | $2.77M | EDGAR |
| 2009-11-16 | Orexigen Therapeutics, Inc. (OREX) Delisted | Buy (P) | +62,000 | $427.8K | EDGAR |
| 2009-11-12 | Orexigen Therapeutics, Inc. (OREX) Delisted | Buy (P) | +138,000 | $956.3K | EDGAR |
| 2009-08-19 | Orexigen Therapeutics, Inc. (OREX) Delisted | Buy (P) | +13,784 | $106.6K | EDGAR |
| 2009-08-18 | Orexigen Therapeutics, Inc. (OREX) Delisted | Buy (P) | +89,426 | $692.7K | EDGAR |
| 2009-08-14 | Orexigen Therapeutics, Inc. (OREX) Delisted | Buy (P) | +413,000 | $3.30M | EDGAR |
| 2009-08-13 | Orexigen Therapeutics, Inc. (OREX) Delisted | Buy (P) | +104,300 | $792.7K | EDGAR |
| 2009-07-24 | Orexigen Therapeutics, Inc. (OREX) Delisted | Buy (P) | +650,000 | $4.88M | EDGAR |
| 2009-06-25 | CADENCE PHARMACEUTICALS INC (CADX) Delisted | Grant (A) | — | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.